Related Experiment Videos
[Flomoxef in the pediatric surgical field]
J Yura1, Y Shimizu, T Hashimoto
1First Department of Surgery, Nagoya City University Medical School.
Insights
Flomoxef (FMOX) is a safe and effective antibiotic for pediatric surgical patients, demonstrating high efficacy and excellent urinary excretion in studies involving biliary atresia and post-operative prophylaxis.
Area of Science:
- Pediatric Surgery
- Infectious Diseases
- Pharmacology
Context:
- Biliary atresia and post-operative conditions in pediatric surgical patients present significant challenges for infection management.
- The need for effective and safe antibiotic options in this vulnerable population is critical.
Purpose:
- To evaluate the safety and efficacy of flomoxef (FMOX) in pediatric surgical patients.
- To assess flomoxef's pharmacokinetic profile, including biliary and urinary excretion.
Summary:
- Flomoxef (FMOX) was administered to pediatric patients with biliary atresia, showing higher peak concentrations in bile than in blood.
- Urinary excretion of FMOX was excellent, with recovery rates ranging from 57.8% to 97.8%.
- In five pediatric surgical cases (one phlegmon, four post-operative prophylaxis in premature infants), FMOX achieved a 100% efficacy rate with no observed side effects.
Impact:
- Flomoxef demonstrates significant potential as a safe and effective antibiotic for treating infections and for prophylactic use in pediatric surgical settings.
- The favorable pharmacokinetic profile, particularly high biliary levels and excellent urinary excretion, supports its use in relevant pediatric surgical conditions.
Abstract:
Basic and clinical studies of flomoxef (6315-S, FMOX) were performed in the pediatric surgical field. The results obtained are summarized as follows: 1. FMOX was administered to 7 pediatric patients with biliary atresia (FMOX 20 mg/kg, i.v.d.). Peak biliary levels of FMOX were obtained at 1 hour after finishing administration by drip infusion, and were higher than those in blood 1 hours after finishing administration by drip infusion. 2. Urinary excretion was excellent, and urinary recovery rates were 57.8-97.8%. 3. FMOX was administered to 5 patients in the pediatric surgical field. One case was phlegmon, and other 4 cases were premature babies for postoperative prophylactic use. Clinical results were excellent in 1 case, good in 4 cases, with an overall efficacy rate of 100%. No clinical and laboratory side effects due to the administration FMOX were observed. It was concluded that FMOX was a safe and effective antibiotic in the pediatric surgical field.